Gufic Biosciences Expands Oncology Portfolio with Further Investment in Australia's Selvax

In a strategic move to bolster its presence in the biotechnology and immunotherapy sectors, Gufic Biosciences Limited (NSE: GUFICBIO) has announced a further investment in Selvax Pty Ltd., a biotechnology firm based in Western Australia.

This latest transaction underscores Gufic's commitment to "Vision 2030" by diversifying into cutting-edge cancer research and development.

Transaction Details

On April 28, 2026, Gufic Biosciences completed the subscription of 378,350 Ordinary shares in Selvax at a price of AUD 20 cents per share.

Total Consideration: USD 50,000 paid in cash.

Revised Shareholding: Following this acquisition, Gufic's total holding in the Australian firm stands at 1,685,350 shares.

Incorporated in 1987, Selvax is a biopharma research company specializing in novel immunology-based treatments for large solid tumors. The company owns proprietary technology designed for both human and veterinary applications (specifically targeting dogs).

The Selvax Advantage:

The immunotherapy under development aims to revolutionize cancer care by:

Targeted Delivery: Focusing specifically on tumor sites to reduce dosages and minimize toxicity.

Systemic Response: Treating one location to trigger a whole-body immune response, potentially clearing untreated metastatic tumors.

Long-term Memory: Inducing immunological memory to protect patients against cancer recurrence.

Broad Application: Potential efficacy against sarcomas, lung, pancreatic, breast, and colorectal cancers.

Strategic Rationale

Gufic's management views the investment as a critical step toward long-term value creation. By participating in Selvax's development phase, Gufic gains:

Technological Access: Direct involvement in proprietary immunology-based research.

Diversification: An entry point into the high-growth oncology sector for both humans and animals.

Global Footprint: Strengthening ties with the Australian biotechnology ecosystem.

Financial Snapshot of Selvax

Selvax has shown a steady increase in its total income over the last three fiscal years (ending June 30):

2025: AUD 356,972
2024: AUD 248,817
2023: AUD 220,435

Shares of Gufic Biosciences Limited was last trading in BSE at Rs. 287.65 as compared to the previous close of Rs. 289.60. The total number of shares traded during the day was 1253 in over 36 trades.

The stock hit an intraday high of Rs. 290.55 and intraday low of 286.10. The net turnover during the day was Rs. 359950.00.

Source : Equity Bulls

Keywords

GuficBiosciences INE742B01025 Pharmaceuticals OncologyPortfolio Investment Selvax Australia